Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

KYOWA KIRIN CO., LTD.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public, Subsidiary

Established: 1949-07-01

Employees: 5.9K

Market Cap: -

Website: http://www.kyowa-kirin.co.jp

Clinical Trials

A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

Phase 2

Completed

Conditions: Multiple Myeloma and Malignant Lymphoma

Interventions: Drug: KRN125(pegfilgrastim), PLR001(plerixafor)
Drug: KRN8601(filgrastim), PLR001(plerixafor)

First Posted Date: 2021-08-16

Last Posted Date: 2023-02-21

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 64

Registration Number: NCT05007652

Locations: 🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵
The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan
🇯🇵
Hospital of the University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan

and more 18 locations

Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia

Active, not recruiting

Conditions: Aplastic Anemia

First Posted Date: 2021-05-03

Last Posted Date: 2024-10-14

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT04870346

Locations: 🇯🇵
Kanazawa University, College of Medical Pharmaceutical and Health Sciences, School of Medicine, Department of Hematology, Kanazawa, Ishikawa Prefecture, Japan

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH

Phase 4

Completed

Conditions: X-linked Hypophosphatemia (XLH)

Interventions: Drug: KRN23

First Posted Date: 2021-04-12

Last Posted Date: 2024-07-09

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT04842032

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳
Guangzhou Women and Children Medical Center, Guangzhou, China
🇨🇳
Shanghai 6th Hospital, Shanghai, China

and more 2 locations

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH

Phase 4

Completed

Conditions: X-linked Hypophosphatemia (XLH)

Interventions: Drug: KRN23

First Posted Date: 2021-04-12

Last Posted Date: 2024-07-09

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 18

Registration Number: NCT04842019

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳
The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China
🇨🇳
Nanfang Hospital, Guangzhou, China

and more 2 locations

Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Phase 3

Completed

Conditions: Hyperphosphatemia

Interventions: Drug: KHK7791

First Posted Date: 2021-02-25

Last Posted Date: 2023-08-02

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 213

Registration Number: NCT04771780

Locations: 🇯🇵
Medical Corporation Seijinkai Ikeda Hospital, Kanoya, Kagoshima, Japan

Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Phase 3

Completed

Conditions: Hyperphosphatemia

Interventions: Drug: KHK7791
Drug: Placebo

First Posted Date: 2021-02-23

Last Posted Date: 2021-10-28

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 169

Registration Number: NCT04766398

Locations: 🇯🇵
Inoue Hospital, Suita, Osaka, Japan

Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis

Phase 3

Completed

Conditions: Hyperphosphatemia

Interventions: Drug: KHK7791

First Posted Date: 2021-02-23

Last Posted Date: 2022-01-11

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 54

Registration Number: NCT04766385

Locations: 🇯🇵
Inoue Hospital, Suita, Osaka, Japan

Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Phase 3

Completed

Conditions: Hyperphosphatemia

Interventions: Drug: KHK7791
Drug: Placebo

First Posted Date: 2021-02-23

Last Posted Date: 2021-09-08

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 165

Registration Number: NCT04767581

Locations: 🇯🇵
Kikuchi medical clinic, Tsukuba, Ibaraki, Japan

A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis

Phase 4

Withdrawn

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: KHK4827-Active
Drug: KHK4827-Placebo

First Posted Date: 2020-11-03

Last Posted Date: 2021-09-30

Lead Sponsor: Kyowa Kirin Co., Ltd.

Registration Number: NCT04614298

Locations: 🇨🇳
Site 07, Changchun, China
🇨🇳
Site 13, Changchun, China
🇨🇳
Site 14, Chongqing, China

and more 22 locations

A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration

Phase 1

Terminated

Conditions: Healthy Volunteers
Wet Age-related Macular Degeneration

Interventions: Drug: Placebo
Drug: KHK4951

First Posted Date: 2020-10-20

Last Posted Date: 2023-05-18

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 116

Registration Number: NCT04594681

Locations: 🇯🇵
Hakata clinic, Fukuoka, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy